A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of oral capecitabine plus intravenous (IV)
gemcitabine in participants with locally advanced or metastatic pancreatic cancer. The
anticipated time on study treatment is 3 to 12 months, and the target sample size is 56
individuals.